In the case of Phamaxis, your "seed" did not grow very well.
I think the report proved again, that the drug cannot receive enough revenue to cover the cost, the cash is quickly reducing and the outcome of next trail is years away.
What a shame they put the words "strong sales" in the report, anyone with basic balance sheet knowledge can tell that the cash burning is a big worry.
Add to My Watchlist
What is My Watchlist?
